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is an evidence-based, multidisciplinary perioperative care
model shown to reduce complications and hospital length
of stay (LOS). While some thoracic ERAS studies were
inconclusive, others demonstrated that ERAS improves
patient outcomes after lung resections and provides more
cost-effective care. We aimed to investigate the effects of
preliminary implementation of an ERAS protocol, in
comparison with conventional care, on lung resection
outcomes at a single academic institution.
Methods. In this observational study, adult patients
undergoing lung resections during the pre-ERAS (April
2014 to September 2015) and post-ERAS (January 2016 to
May 2017) periods were identified. Relevant de-
mographic, preoperative, anesthesia, and surgical vari-
ables were collected. Pre-ERAS and post-ERAS cohorts
were compared in terms of hospital LOS, postoperative
complications, and 30-day outcomes.
Results. We identified 264 patients, half in each cohort.
Pre-ERAS and post-ERAS groups were similar withAccepted for publication Jun 3, 2020.
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27599-7065; email: jason_long@med.unc.edu.respect to age, race, and comorbidities. There were no
significant differences in LOS, complications, 30-day
readmission and mortality rates, or patient-reported out-
comes. Of the patients with prolonged LOS, 31% had
pulmonary complications, almost half of which were
prolonged air leaks. ERAS adherence rate was approxi-
mately 60%.
Conclusions. In the first year of implementation,
median LOS, complications, and 30-day outcomes did
not differ significantly between the pre-ERAS and post-
ERAS groups. Prolonged air leaks commonly led to
prolonged LOS; therefore, thoracic ERAS protocols
could include interventions to reduce air leak and
consideration for discharging patients with chest tubes
placed to Heimlich valves. Buy-in and adherence to a
new protocol are necessary for implementation to be
effective.n the 1990s, Henrik Kehlet developed the concept ofIenhanced recovery after surgery (ERAS), an evidence-
based, multidisciplinary perioperative care model. This
model has been shown to reduce complications and
hospital length of stay (LOS).1,2 The 3 phases of a thoracic
ERAS pathway are as follows: the preoperative phase
includes counseling, nutrition, and optimization of
comorbidities; the intraoperative phase incorporates
multimodal analgesic medications and techniques
(including regional anesthesia with epidural and/or
intercostal block [ICB]), limiting crystalloids, and mini-
mally invasive surgery (robotic-assisted thoracoscopicsurgery [RATS] or video-assisted thoracoscopic surgery
[VATS]) where possible; and finally, the postoperative
phase involves use of incentive spirometry, early mobi-
lization, early chest tube, and urinary catheter removal.2,3
Initial thoracic ERAS studies were mostly case series;
the lack of a control group increases risk of bias and limits
the ability to attribute improvements in care to ERAS.4-6
While some recent thoracic ERAS studies were incon-
clusive,7 others showed that ERAS improves outcomes
after lung resections and provides more cost-effective
care.8,9 Objectives of this study were (1) to investigate
the effect of ERAS implementation—in comparison with
conventional care—on pulmonary resection outcomes at
the University of North Carolina (UNC) hospitals; (2)
assess the association between demographic, preopera-
tive, anesthesia, and surgical factors on LOS, morbidity,
and mortality; and finally, (3) describe challenges of ERAS
implementation.
Table 1. University of North Carolina Thoracic ERAS Protocol
Preoperative Intraoperative Postoperative
Tobacco cessation Incentive spirometry
education




1000 mg PO, Celebrex 200 mg
PO, Pregabalin 100 mg PO
Consumption of clear fluids up
until 2 h before surgery.
Analgesia (VATS/RATS):
1. Intercostal blocks (T2-T10 levels) with
1:1
mix of 0.25% plain bupivacaine þ
liposomal bupivacaine.
2. Ketamine infusion: 0.25 mgkgh
Analgesia (thoracotomy):
Thoracic epidural: 0.25% plain
bupivacaine infusion, 3-6 mL/h
Fluids:
Establish and maintain euvolemia;
frequent arterial blood gas
interpretation.
Blood pressure:
Maintain systolic blood pressure >20%
baseline.




 Pressure control ventilation
 Recruitment breaths q30min
 2 lung: tidal volume 5-8 mL/kg (3-5
for ESLD) IBW, FiO2 <0.5 if
possible, PEEP 5
 1 lung: tidal volume 4-7 mL/kg IBW,
FiO2 1.0 and wean by 0.1 q5min,
PEEP 5-8 (3-5 for ESLD)
 Respiratory rate: Keep PaCO2 within
10 mm Hg of baseline
Antibiotic prophylaxis
Prevention of Postoperative Nausea with
Dexamethasone
Venous thromboembolism prophylaxis
Prevention of intraoperative hypothermia
Minimally invasive surgical technique





 Ketorolac 15 mg IV q8h or ibuprofen
800 mg PO q8h  24 h on POD 0.
 Transition to Ibuprofen 600 mg PO
q6hr PRN on POD 1 and until
discharge.
 Gabapentin 300 mg PO TID until
discharge.
 Tylenol 650 mg PO QID until
discharge.
Early mobilization
Early chest tube removal (24-h
output <250 mL and no air leak)
Early urinary catheter removal
ERAS, enhanced recovery after surgery; ESLD, end-stage lung disease; FiO2, fraction of inspired oxygen; IBW, ideal body weight; IV, intravenous; NSAID,
nonsteroidal antiinflammatory drug; PaCO2, partial pressure of carbon dioxide; PEEP, positive end-expiratory pressure; PO, by mouth; POD, post-
operative day; PRN, as needed; q, every; QID, 4 times a day; RATS, robotic-assisted thoracoscopic surgery; TID, 3 times a day; VATS, video-assisted
thoracoscopic surgery.Patients and Methods
Study Design
In this retrospective observational study, consecutive
adult patients (18 years of age) undergoing pulmonary
resections (wedge resection, segmentectomy, lobectomy,
and bilobectomy) during pre-ERAS (April 2014 to
September 2015) and post-ERAS (January 2016 to May
2017) periods were identified from UNC’s Thoracic Sur-
gery Database. Only a patient’s first thoracic operation
was eligible; redo surgeries and unexpected returns to the
operating room were excluded.
We developed our thoracic ERAS pathway with
fundamental elements of previously publishedprotocols.10 Evidence-based practices for multimodal
opioid-sparing analgesia, including ICB, percutaneous
injection of bupivacaine or liposomal bupivacaine under
direct vision, as previously described by Van Haren and
colleagues11; minimally invasive surgery; pulmonary toi-
leting; and chest tube management, were applied to our
protocol (Table 1).
Because ERAS was not fully implemented until January
2016, resections performed during this ERAS wash-in
period (October to December 2015) were excluded. Pa-
tients who simultaneously underwent esophagectomy
(n ¼ 2), pneumonectomy (n ¼ 1), or coronary artery
bypass grafting (n ¼ 1), and trauma patients (n ¼ 4) were
excluded. Patient demographics, baseline clinical
Table 2. Patient Baseline Characteristics, Stratified by Pre-ERAS and Post-ERAS Implementation
Variable Pre-ERAS Post-ERAS P Value
Patients 133 (50) 131 (50)
Age, y 64 (55-70) 61 (54-68) .19
Male 67 (50) 50 (38) .05
Race
White 100 (75) 92 (70) .41
Black 27 (20) 28 (21) .88
Other 6 (5) 11 (8) .22
BMI, kg/m2 27 (24-33) 27 (23-31) .26
Comorbidities
Hypertension 73 (55) 60 (46) .18
Congestive heart failure 12 (9) 4 (3) .07
Coronary artery disease 20 (15) 13 (10) .26
Peripheral vascular disease 13 (10) 13 (10) .99
Diabetes, insulin-dependent 6 (5) 3 (2) .50
Renal insufficiency 5 (4) 6 (5) .77
Smoking status
Never 35 (26) 36 (27) .89
Former 69 (52) 72 (55) .62
Current 29 (22) 23 (18) .44
Smoked within 4 wk of surgery 34 (26) 29 (22) .56
Preoperative or longstanding steroid use 37 (28) 64 (49) <.01
Preoperative chemotherapy 29 (22) 19 (15) .15
Preoperative radiation 27 (20) 15 (11) .06
Prior cardiothoracic surgery 15 (11) 17 (13) .71
Primary diagnosis
Benign lung disease 25 (19) 24 (18) .99
Lung cancer 77 (58) 69 (53) .46
Pulmonary metastastectomy 31 (23) 32 (24) .89
FEV1, % 83 (72-97) 83 (66-97) .88
DLCO, % 70 (57-84) 75 (62-87) .16
Karnofsky performance scale index, % 100 (90-100) 90 (90-100) .44
ASA score
1 0 (0) 0 (0) .
2 13 (10) 12 (9) .99
3 96 (72) 98 (75) .68
4 24 (18) 21 (16) .74
Thoracic revised cardiac risk index
0 104 (78) 1112 (86) .15
1-1.5 25 (19) 15 (11) .12
2 4 (3) 4 (3) .99
Values are n (%) or median (interquartile range).
ASA, American Society of Anesthesiologists; BMI, body mass index; DLCO, diffusing capacity of lung for carbon monoxide; ERAS, enhanced recovery after
surgery; FEV1, forced expiratory volume in 1 second.measures, and surgical characteristics were abstracted
from electronic medical records. The Karnofsky perfor-
mance scale index12 and thoracic revised cardiac risk in-
dex (ThRCRI) (a validated cardiac risk assessment tool)13
were assessed.
Primary outcomes were hospital LOS, total post-
operative complications (defined using The Society of
Thoracic Surgeons [STS] criteria),14 30-day readmission,
and mortality. LOS was categorized as being expected or
normal or prolonged based on procedure type, with LOSgreater than 2 days after wedge resection, LOS greater
than 3 days after segmentectomy, and LOS greater than 5
days after lobe resection or bilobectomy being considered
prolonged hospitalizations.15-22
Statistical Analyses
Patient demographics, surgical characteristics, and
postoperative outcomes were compared between pre-
ERAS and post-ERAS patients using Fisher’s exact
and Wilcoxon-Mann-Whitney tests, where appropriate.
Table 3. Intraoperative Characteristics, Stratified by Pre-ERAS and Post-ERAS Implementation
Variable Pre-ERAS 133 (50%) Post-ERAS 131 (50%) P Value
Patients 133 (50) 131 (50)
Preoperative medications
Acetaminophen 7 (5) 102 (78) <.0001
Pregabalin 5 (4) 85 (65) <.0001
Celecoxib 1 (1) 73 (56) <.0001
Procedure
Wedge resection 85 (64) 74 (56) .22
Segmentectomy 0 (0) 1 (1) .50
Lobectomy 46 (35) 56 (43) .21
Bilobectomy 2 (2) 0 (0) .50
Robotic surgery 0 (0) 15 (11) <.0001
Thoracotomy 3 (2) 3 (2) .99
Surgery time, min 121 (67-182) 119 (81-193) .34
Anesthesia time, min 159 (113-217) 173 (126-232) .18
Intraoperative medications
Ketorolac 3 (2) 26 (20) <.0001
Dexamethasone 44 (33) 69 (53) .002
Vasopressin 9 (7) 51 (39) <.0001
Norepinephrine 1 (1) 18 (14) <.0001
Regional block type
Intercostal nerve block 90 (68) 102 (78) .07
Epidural 0 (0) 0 (0) .
Intercostal nerve block and epidural 43 (32) 29 (22) .07
Intercostal nerve block type
Bupivacaine alone 133 (100) 37 (28) <.0001
Liposomal bupivacaine alone 0 (0) 61 (47) <.0001
Bupivacaine and liposomal bupivacaine 0 (0) 33 (25) <.0001
Transfusion 0 (0) 0 (0) .
Total crystalloids, mL 2000 (900-1600) 800 (496-1100) <.0001
Total colloids, mL 0 (0-0) 250 (0-500) <.0001
Morphine equivalents, mg 25 (22-32) 20 (15-25) <.0001
Values are n (%) or median (interquartile range).
ERAS, enhanced recovery after surgery.A P value less than or equal to .05 was considered
statistically significant. Linear regression was used to
assess trends in patient-reported satisfaction and pain
scores (data from Hospital Consumer Assessment of
Healthcare Providers and Systems and Press Ganey).
Cox proportional hazards regression was used to esti-
mate the effect of ERAS on inpatient complications and
30-day readmission. Multivariable hazards regression
was used to estimate the effect of ERAS on outcomes,
after adjusting for age, gender, steroid use, ThRCRI,
intraoperative crystalloids, colloids, and morphine
equivalents. Age, crystalloids, colloids, and morphine
equivalents were modeled as restricted quadratic splines
to allow for the most flexibility. Multivariable logistic
regression was used to assess the effect of ERAS on
prolonged LOS, after adjusting for variables described
previously.
Sensitivity analyses were performed to assess whether
potential risk groups were more impacted by ERAS.
Specifically, interaction terms were used to assesswhether age (categorized as <70 and 70 years old) and
thoracic revised cardiac risk index (categorized as 0 and
1) modified the effect of ERAS on any complication and
prolonged LOS, respectively.
All analyses were performed in SAS version 9.4 (SAS
Institute, Cary, NC). The UNC institutional review board
provided ethical approval of the study (institutional re-
view board #15-1841).Results
Overall, 264 patients were included; 133 (50%) underwent
surgery pre-ERAS, and 131 (50%) underwent surgery
post-ERAS. The groups were comparable in terms of age,
race, body mass index, comorbidities, smoking, preop-
erative chemoradiation, prior cardiothoracic surgery,
primary diagnosis, pulmonary function tests, Karnofsky
performance scale index, American Society of Anesthe-
siologists score, or ThRCRI (Table 2). Post-ERAS patients
were less likely to be male (50% vs 38%; P ¼ .05) and more
Table 4. Adjusted Effect of ERAS Implementation, Compared
With Pre-ERAS Implementation, on Inpatient Complications
and 30-Day Outcomes
Variable Pre-ERAS Post-ERAS HR (95% CI)a
Inpatient complications
Pulmonary 20 (15) 20 (15) 0.79 (0.27-2.34)
Cardiovascular 12 (9) 9 (7) 1.07 (0.27-4.20)
Urinary 10 (8) 17 (13) 0.84 (0.25-2.88)
Infection 2 (2) 1 (1) NA
Hemolytic 2 (2) 2 (2) NA
Gastrointestinal 2 (2) 0 (0) NA
Neurological 5 (4) 1 (1) NA
Other 4 (3) 6 (5) 0.93 (0.12-7.50)
Any complication 36 (27) 44 (34) 1.25 (0.62-2.51)
30-d mortality 0 (0) 2 (2) NA
30-d readmission 11 (8) 13 (10) 1.85 (0.52-6.66)
OR (95% CI)a
Prolonged LOSb 65 (49) 54 (49) 1.55 (0.69-3.47)
aAdjusted for gender, age, preoperative or long-standing steroid use,
thoracic revised cardiac risk index, intraoperative crystalloids, intra-
operative colloids, and intraoperative morphine equivalents; age, crys-
talloids, colloids, and morphine equivalents were modeled as restricted
quadratic splines; bProlonged LOS was defined as a LOS >2 days after
wedge resection, >3 days after segmentectomy, and >5 days after lobe
resection or bilobectomy.
Values are n (%).
CI, confidence interval; ERAS, enhanced recovery after surgery; HR,
hazard ratio; LOS, length of stay; NA, not analyzable; OR, odds ratio.likely to have preoperative or longstanding steroid use
(systemic intravenous or oral steroids), a variable
routinely collected by the STS (28% vs 49%; P < .01). Of





on HCAHPS data, no
changes in patient-reported
overall satisfaction or pain
management were seen
throughout pre–enhanced
recovery after surgery and
post–enhanced recovery
after surgery time periods.steroids and also found a significant difference (35% vs
56%; P ¼ .001).
Post-ERAS patients had higher use of preoperative
medications (acetaminophen, pregabalin, and celecoxib),
RATS, and intraoperative medications (ketorolac, dexa-
methasone, vasopressin, and norepinephrine). Cohorts
differed significantly in ICB type, total crystalloids and
colloids, and morphine equivalents (Table 3). No differ-
ences were seen across procedure type, surgery or anes-
thesia time, or regional block type.
Median LOS among all patients was 4 (interquartile
range, 2-6) days. Of the 119 patients with prolonged LOS,
37 (31%) had pulmonary complications, almost half of
which (n ¼ 15, 41%) were prolonged air leaks (PALs) (>5
days, as defined by the STS).14 There were no significant
differences in complications, prolonged LOS, 30-day
mortality, or readmission between cohorts (Table 4).
Even after adjustment, no differences in complications
(hazard ratio, 1.25; 95% confidence interval [CI], 0.62-
2.51), 30-day readmission (hazard ratio, 1.85; 95% CI, 0.52-
6.66), or prolonged LOS (odds ratio, 1.55; 95% CI, 0.69-
3.47) were seen (Table 4). No difference in the impact of
ERAS on complications and prolonged LOS was seen
among older (P ¼ .34 and P ¼ .55, respectively) or high-
risk patients (P ¼ .34 and P ¼ .26, respectively). There
were only 2 cases of postoperative mortality (both post-
ERAS). No changes in patient-reported satisfaction or
pain management were seen (Figures 1 and 2).
Among patients with prolonged LOS, no difference in
PALs was seen across pre-ERAS and post-ERAS imple-
mentation (14% vs 11%; P ¼ .79). Neither low preopera-
tive diffusing capacity for carbon monoxide (<50%) (19%
vs 10%; P ¼ .28) nor forced expiratory volume in 1 second
(median 85.5 vs 82.3; P ¼ .66) was associated with PALs.
Figure 2. Trends in mean
Press Ganey satisfaction
and pain scores based on
Press Ganey data. No
changes in patient-reported
overall satisfaction or pain
management were seen
throughout pre–enhanced
recovery after surgery and
post–enhanced recovery
time periods.PALs were not associated with steroid use but were
associated with smoking (P ¼ .03).Comment
We evaluated preliminary progress in thoracic ERAS
implementation at our institution. Pre-ERAS and post-
ERAS patients were comparable preoperatively and
only differed in gender and steroid use. Frequent steroid
use was an unintended variable that could negatively
affect post-ERAS outcomes.23 Cohorts differed in intra-
operative goal-directed fluid management and multi-
modal opioid-sparing analgesia, both key ERAS
components. Most patients had minimally invasive sur-
gery. Fifteen post-ERAS patients underwent RATS, which
is shown to reduce LOS and 30-day mortality when
compared with VATS and thoracotomies.24,25
Based on preliminary results, median hospital LOS,
complications, 30-day readmission and mortality, patient-
reported satisfaction, and pain did not differ between
cohorts. Median LOS was 4 days for both cohorts overall,
3 days for both VATS wedge resection groups, and 5 days
for both VATS lobectomy groups; these are comparable
with national medians.15-22 This was consistent with a
Brunelli and colleagues7 study that showed no benefit
from ERAS on LOS, cardiopulmonary complications, 30-
day and 90-day mortality, and readmissions. However,
this contradicts recent studies that showed decreased
LOS and complications and improved patient satisfaction
and pain with ERAS.8,9,26 One potential reason is that
certain ERAS elements (eg, VATS and preoperative
counseling) were utilized pre-ERAS. VATS is associated
with lower risk and uncomplicated recovery, and thus
may not require ERAS.7 This concept was demonstrated
by Van Haren and colleagues,11 who showed decreasedLOS and cardiopulmonary morbidity with ERAS after
thoracotomy but not after minimally invasive surgery.
Our data represent a preliminary snapshot of thoracic
ERAS implementation at one institution, where pre-
ERAS median LOSs were already consistent with na-
tional medians.15-22 It was difficult to observe significant
differences in outcomes given our small sample size and
initial low ERAS compliance (certain medications were
not always clinically indicated) (Table 3). ERAS imple-
mentation is a large-scale quality improvement effort
requiring multidisciplinary education and buy-in. We
faced many barriers to success, including communication
breakdown, staff turnover, lack of resources for data
collection and compliance assessment, and the need to
update pathways with best-available evidence.27-29
Higher ERAS compliance (>75%) has been shown to
improve outcomes.30 Concurrent efforts to improve pa-
tient safety and outcomes also render it challenging to
determine the overall effect of ERAS.
PALs often extended LOS for our patients. The noted
association of PALs with smoking emphasizes the
importance of preoperative tobacco cessation. Yoo and
colleagues31 estimated the economic burden of PAL to
be $6512 higher. The 2019 Guidelines for Enhanced
Recovery After Lung Surgery mention the effect of
chest tube suction and digital drainage systems on
PALs,32 but thoracic ERAS protocols could also include
interventions such as biodegradable polymeric lung
sealants,33,34 buttressing staple lines,35,36 or imple-
mentation of the Greer and colleagues37 Standardized
Approach to Air Leak Reduction protocol. Given the
steep learning curve of RATS, constant improvement of
surgical technique could reduce PAL.38 We are also
discharging patients with PAL earlier with chest tubes
placed to Heimlich valves.39,40
Finally, 40% of patients experienced transportation-
related discharge delays. UNC has reduced these delays
by providing taxi vouchers and opening a discharge
lounge. This phenomenon reveals a potential limitation of
using LOS as a metric. Other metrics of ERAS success
could include postoperative oxygen requirement and
functional recovery metrics (time to return to work or
activities of daily living).
Strengths of this study include initial comparability of
groups, large number of variables collected, and minimal
missing data. However, study limitations include small
sample size from one institution and frequent
transportation-related discharge delays. Nonresponse
bias and memory bias may influence survey pain scores.
Lack of a concurrent control group could introduce bias
given potential confounding factors. Having VATS as a
common element pre-ERAS and post-ERAS may mask
the effect of other ERAS elements on outcomes.7 Frequent
post-ERAS steroid use could impair wound healing and
increase infections.23 In addition to low ERAS compli-
ance,30 the introduction of RATS might also affect post-
ERAS outcomes.
We have discussed initial challenges of thoracic ERAS
implementation and strategies to address them. Low
compliance, PALs, and discharge delays may offset ad-
vantages seen with ERAS. Further studies are warranted
as we implement updates from the 2019 guidelines32 to
improve thoracic ERAS implementation, foster a culture
of ongoing quality improvement, and investigate its cost-
effectiveness.
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